Research And Development
Shaping the future of noninvasive diagnostics with artificial intelligence.
Strong Scientific Expertise
Widely used, researched and validated patented test
Evaluating serum biomarkers LiverFast surrogates of liver fibrosis and steatosis could identify risks in a clinical population experiencing sars-cov2 infection (COVID).
Lead Author
Dr. Maryna Raskin
Study Population
Miscellaneous n=10,623
LIVERFASt™ & LIVERFASt Select
Conclusion
LIVERFASt™ Steatosis and Fibrosis scores are NITs that could be used to screen populations at risk of MetS and liver disease to identify those at risk of COVID-19.
Location
Health Catalyst US
Simulating clinical confidence intervals for black-box algorithmic predictions of liver steatosis.
Lead Author
Dr. Brian Cohn
Study Population
IT simulations
10,000 replicates per biomarker
Conclusion
Noise injection allows for nuanced tailoring & interpretation of results inferred by an AIA. We equip clinicians with an interactive tool to contextualize therapeutic expectations & aid in patient education towards adherence endpoints. In effect, providing a new, nuanced view of how AIA assess LD.
Location
Fibronostics US
Machine learning technology for evaluation of liver fibrosis, inflammation activity and steatosis (LiverFast™).
Lead Author
Abhishek Aravind
Study Population
NAFL to advanced NASH n=2862
LIVERFASt™
Conclusion
The modified SAF scoring system generated by LIVERFASt™ provided a simple & convenient diagnosis of NAFLD & NASH, and staging of the three liver lesions as shown in a cohort of SEA.
Location
Fibronostics Singapore
Predictive value of non-invasive methods liverfast, acoustic radiation force impulse (ARFI), fib-4 & apri to identify the natural phases of chb infection from nuh chb study cohort of singapore.
Lead Author
Prof. Lim Seng Gee
Study Population
CHB n=724, LIVERFASt™
Conclusion
LF-Fibrosis & LF-Activity are reliable tools for screening HBV infected patients & for detecting phase-related liver disease, with better NPV than APRI or FIB-4. Management of HBV pts could be improved by LF tests.
Location
National University Health System (NUHS) Singapore
